WuXi Biologics (Cayman) Inc. (WXXWY)
OTCMKTS · Delayed Price · Currency is USD
8.90
-0.19 (-2.06%)
Nov 4, 2025, 3:58 PM EST
WuXi Biologics Revenue
WuXi Biologics had revenue of 9.95B CNY in the half year ending June 30, 2025, with 17.21% growth. This brings the company's revenue in the last twelve months to 20.05B, up 17.16% year-over-year. In the year 2024, WuXi Biologics had annual revenue of 18.68B with 9.63% growth.
Revenue (ttm)
20.05B CNY
Revenue Growth
+17.16%
P/S Ratio
6.50
Revenue / Employee
1.59M CNY
Employees
12,575
Market Cap
18.19B USD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 18.68B | 1.64B | 9.63% |
| Dec 31, 2023 | 17.03B | 1.77B | 11.56% |
| Dec 31, 2022 | 15.27B | 4.98B | 48.38% |
| Dec 31, 2021 | 10.29B | 4.68B | 83.35% |
| Dec 31, 2020 | 5.61B | 1.63B | 40.88% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Jushi Holdings | 256.36M |
| Glass House Brands | 221.55M |
| Elite Pharmaceuticals | 105.45M |
| Silence Therapeutics | 27.17M |
| China New Energy Group Co. | 12.51M |
| Northwest Biotherapeutics | 1.09M |
WuXi Biologics News
- 13 days ago - WuXi Biologics Included in Hang Seng Corporate Sustainability Benchmark Index - PRNewsWire
- 15 days ago - WuXi Biologics Honored with 2025 Global Customer Value Leadership Recognition by Frost & Sullivan - PRNewsWire
- 25 days ago - WuXi Biologics Receives MSCI AAA ESG Rating for Third Consecutive Year - PRNewsWire
- 5 weeks ago - WuXi Biologics Launches WuXia™4.0, Targeted Integration Cell Line Platform TrueSite TI™,to Accelerate Biologics Development with High Titer and Superior Stability - PRNewsWire
- 6 weeks ago - WuXi Biologics Selected as Constituent of FTSE4Good Index Series for Fifth Consecutive Year - PRNewsWire
- 6 weeks ago - Chinese biotechs get a shot in the arm from policy support, licensing deals - South China Morning Post
- 6 weeks ago - Three WuXi Biologics Manufacturing Facilities Receive GMP Certification from Türkiye İlaç ve Tibbi Cihaz Kurumu (TITCK) - PRNewsWire
- 7 weeks ago - WuXi Biologics Achieves "CDMO of the Year" Among Three Prestigious IMAPAC Awards - PRNewsWire